Market Access Anglonordic Life Science 2026: A focus on execution The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
Digital Augmented intelligence: The next-gen engine for biopharma in... Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.
News Number of UK biotech companies rising, says report A report has found that the number of life sciences companies domiciled in the UK has grown by nearly a quarter in the last few years.
Sales & Marketing A fast start to 2026 signals continued investor confidence i... Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.
Digital AI's promise, biotech's peril: How unequal access to computi... Many biotechs remain locked out of the AI revolution by a combination of cost, complexity, and lack of access to state-of-the-art infrastructure.
News UK biotech sees "strong finish" to 2025 financing 2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.